111614
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
昆明某医院过去两年中耐碳青霉烯类肠杆菌科细菌耐药性分析
Received 10 July 2025
Accepted for publication 23 November 2025
Published 3 December 2025 Volume 2025:18 Pages 6335—6351
DOI https://doi.org/10.2147/IDR.S552889
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 5
Editor who approved publication: Dr Hemant Joshi
Zhineng Xu,1,2 Lingnan Xu,1,2 Dehua Liu1
1Department of Laboratory, The First Hospital of Kunming, Kunming, Yunnan, 650032, People’s Republic of China; 2School of Medicine, Kunming University, Kunming, Yunnan, 650214, People’s Republic of China
Correspondence: Dehua Liu, The First Hospital of Kunming, 504 Qingnian Road, Xishan District, Kunming, Yunnan, 650032, People’s Republic of China, Tel +86 158 7799 0175, Email 2539415043@qq.com
Objective: To examine the species distribution, clinical prevalence, antimicrobial profiles, and carbapenemase phenotypes of carbapenem-resistant Enterobacterales (CRE) isolated from a tertiary hospital over the past two years, thereby providing a reference for clinical anti-infection strategies and hospital infection control measures.
Methods: A retrospective analysis was performed to examine the distribution of CRE strains isolated from inpatients at a tertiary hospital between 2023 and 2024, their resistance profiles to commonly used antibiotics and carbapenemase phenotypes.
Results: A total of 239 distinct CRE strains were identified between 2023 and 2024, predominantly in sputum, urine, and blood samples. The primary species of CRE include Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis. These CRE strains were mainly isolated from departments such as geriatrics, intensive care units (ICU), and respiratory medicine. Among the 239 CRE isolates, there was a notably high resistance rate to cephalosporins, enzyme inhibitor combinations, aminoglycosides, and quinolones, exceeding 85%, with carbapenems exhibiting a resistance rate of over 90%. Conversely, the resistance rates to tigecycline, ceftazidime/avibactam, and polymyxin B were 1.26%, 24.24%, and 5.43%, respectively. The majority of strains (74.06%) produced class A serine carbapenemases, specifically the KPC type.
Conclusion: The CRE isolation and resistance rates in this hospital are similar to international trends, both showing an upward trend, and comparison with domestic data reveals significant regional differences. CRE infections are difficult to treat and have a high mortality rate. Therefore, to meet the needs of Infection Prevention and Control, it is necessary to strengthen the monitoring of CRE resistance in this institution, contributing to the prevention, control, and clinical management capabilities for infections.
Keywords: Enterobacterales, carbapenemase-resistant, drug resistance, enzyme types
1Department of Laboratory, The First Hospital of Kunming, Kunming, Yunnan, 650032, People’s Republic of China; 2School of Medicine, Kunming University, Kunming, Yunnan, 650214, People’s Republic of China
Correspondence: Dehua Liu, The First Hospital of Kunming, 504 Qingnian Road, Xishan District, Kunming, Yunnan, 650032, People’s Republic of China, Tel +86 158 7799 0175, Email 2539415043@qq.com
Objective: To examine the species distribution, clinical prevalence, antimicrobial profiles, and carbapenemase phenotypes of carbapenem-resistant Enterobacterales (CRE) isolated from a tertiary hospital over the past two years, thereby providing a reference for clinical anti-infection strategies and hospital infection control measures.
Methods: A retrospective analysis was performed to examine the distribution of CRE strains isolated from inpatients at a tertiary hospital between 2023 and 2024, their resistance profiles to commonly used antibiotics and carbapenemase phenotypes.
Results: A total of 239 distinct CRE strains were identified between 2023 and 2024, predominantly in sputum, urine, and blood samples. The primary species of CRE include Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis. These CRE strains were mainly isolated from departments such as geriatrics, intensive care units (ICU), and respiratory medicine. Among the 239 CRE isolates, there was a notably high resistance rate to cephalosporins, enzyme inhibitor combinations, aminoglycosides, and quinolones, exceeding 85%, with carbapenems exhibiting a resistance rate of over 90%. Conversely, the resistance rates to tigecycline, ceftazidime/avibactam, and polymyxin B were 1.26%, 24.24%, and 5.43%, respectively. The majority of strains (74.06%) produced class A serine carbapenemases, specifically the KPC type.
Conclusion: The CRE isolation and resistance rates in this hospital are similar to international trends, both showing an upward trend, and comparison with domestic data reveals significant regional differences. CRE infections are difficult to treat and have a high mortality rate. Therefore, to meet the needs of Infection Prevention and Control, it is necessary to strengthen the monitoring of CRE resistance in this institution, contributing to the prevention, control, and clinical management capabilities for infections.
Keywords: Enterobacterales, carbapenemase-resistant, drug resistance, enzyme types